ID
IDP.F Biogen Inc
- Market cap
- EUR 33.4B
- P/E
- 113.5x
- P/B
- 1.97x
- ROE
- 2.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IDP.F undervalued?
Graham numberThe Graham number of Biogen Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biogen Inc fundamental analysis
No fundamental analysis for Biogen Inc yet.
Biogen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimuma…
Full company profileBiogen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biogen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.4B | 12.3B | 13.5B | 14.4B | 13.4B | 11.0B | 10.2B | 9.84B | 9.68B | 9.89B | 10.7B |
| Gross Profit | 9.97B | 10.6B | 11.6B | 12.4B | 11.6B | 8.87B | 7.90B | 7.30B | 7.37B | 7.49B | 7.78B |
| Operating Income | 5.65B | 5.53B | 6.00B | 7.04B | 4.45B | 2.81B | 2.90B | 1.85B | 2.28B | 2.47B | 1.90B |
| EBITDA | - | 6.46B | 7.12B | 7.99B | 5.73B | 2.88B | 3.27B | 2.04B | 2.83B | 2.60B | 1.89B |
| Net Income | 3.70B | 2.54B | 4.43B | 5.89B | 4.00B | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B | 529M |
| EPS | - | 12 | 22 | 34 | 26 | 11 | 21 | 8.01 | 11 | 8.81 | 3.58 |
| Balance Sheet | |||||||||||
| Total Assets | 22.9B | 23.7B | 25.3B | 27.2B | 24.6B | 23.9B | 24.6B | 26.8B | 28.0B | 29.4B | 32.1B |
| Total Liabilities | 10.7B | 11.1B | 12.3B | 13.9B | 13.9B | 12.9B | 11.2B | 12.0B | 11.3B | 11.2B | 13.1B |
| Shareholders' Equity | 12.1B | 12.6B | 13.0B | 13.3B | 10.7B | 10.9B | 13.4B | 14.8B | 16.7B | 18.3B | 18.9B |
| Cash & Short-term Investments | 2.33B | 1.57B | 1.22B | 2.91B | 1.33B | 2.26B | 3.42B | 1.05B | 2.38B | 3.01B | 1.30B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.59B | 4.55B | 6.19B | 7.08B | 4.23B | 3.64B | 1.38B | 1.36B | 2.88B | 2.20B | 2.31B |
| Capital Expenditure | 728M | 867M | 771M | 515M | 425M | 258M | 240M | 334M | 360M | 235M | 657M |
| Free Cash Flow | - | 2.59B | 5.30B | 6.41B | 3.68B | 3.35B | 1.38B | 1.03B | 2.52B | 1.97B | 1.66B |
| Ratios | |||||||||||
| ROE | 30.5% | 20.1% | 34.0% | 44.1% | 37.4% | 14.3% | 22.8% | 7.8% | 9.8% | 7.1% | 2.8% |
| ROA | 16.2% | 10.7% | 17.5% | 21.6% | 16.3% | 6.5% | 12.4% | 4.3% | 5.8% | 4.4% | 1.6% |
| Net Profit Margin | 32.3% | 20.7% | 32.9% | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.1% | 4.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Biogen Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 134M | 0.63 | 5.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Biogen Inc
- Insiders 0.19%
- Institutions 98.87%
- Public & others 0.94%
- Shares outstanding 148M
- Free float 147M
Biogen Inc company profile
- Company name
- Biogen Inc
- Ticker
- IDP.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7,500
- Fiscal year end
- December
- Address
- 225 Binney Street, Cambridge, MA, United States, 02142
- Phone
- 617 679 2000
- Website
- biogen.com
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen Inc management
10- Mr. Christopher A. ViehbacherPresident, CEO & Director · born 1961
- Ms. Robin C. KramerExecutive VP & CFO · born 1966
- Ms. Nicole MurphyExecutive VP and Head of Pharmaceutical Operations & Technology · born 1973
- Dr. Priya Singhal M.D., M.P.H.Executive VP & Head of Development · born 1968
- Mr. Sean GodboutVP, Chief Accounting Officer & Global Corporate Controller · born 1974
- Mr. Guy HadariChief Information Officer
- Mr. Tim Power M.B.A., Ph.D.Head of Investor Relations
- Mr. Michael John Parini J.D.Chief Legal Officer · born 1974
- Ms. Natacha GassenbachChief Communication Officer & Head of Corporate Affairs
- Mr. Adam Keeney Ph.D.Executive VP & Head of Corporate Development · born 1977